文献速递母胎医学

纳入胎儿分数扩增的产前游离DNA检测对22q11.2微缺失筛查具有高阳性预测值

High positive predictive value 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplification.
PubMed 文献 · Prenat Diagn · 2024-04-15

本研究评估纳入胎儿分数扩增的产前游离DNA筛查对22q11.2微缺失的临床性能。379428例符合条件患者中76例筛查阳性,22例有诊断检测结果且全部为真阳性,阳性预测值为100%(95%CI 84.6%-100%)。作者认为该筛查在一般和高危人群中均显示高阳性预测值。

要点

  • 纳入胎儿分数扩增的产前cfDNA筛查22q11.2微缺失的阳性预测值为100%(95%CI 84.6%-100%)。
  • 76例筛查阳性中仅22例(29.7%)有诊断检测结果,全部确认为真阳性。
  • 筛查阳性孕妇的超声表现与已知22q11.2缺失综合征相关表现一致。

核心结论

  • 纳入胎儿分数扩增的22q11.2微缺失筛查在一般和高危人群队列中均显示高阳性预测值。

研究设计与样本

  • 研究队列为接受纳入胎儿分数扩增的产前游离DNA筛查(Prequel,Myriad Genetics, Inc.)并符合额外入选标准的患者。
  • 通过持续质量改进的常规流程获取妊娠结局。
  • 有诊断检测结果的样本用于计算阳性预测值。

主要发现

  • 379428例患者符合研究入选标准,其中76例筛查阳性提示新发22q11.2微缺失。
  • 22例(29.7%)有可用的诊断检测结果,全部22例确认为真阳性,阳性预测值为100%(95%CI 84.6%-100%)。
  • 该性能基于胎儿分数范围5.9%-41.1%(均值23.0%)、体重指数22.3-44.8(均值29.9)、检测时孕龄10.0周-34.6周(中位数12.7周)的病例。
  • 筛查阳性妊娠的超声表现与已知与22q11.2缺失综合征相关的表现一致。

局限性

  • 76例筛查阳性中仅22例(29.7%)有诊断检测结果可用于计算阳性预测值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: 22q11.2 deletion syndrome (DS) is a serious condition with a range of features. The small microdeletion causing 22q11.2DS makes it technically challenging to detect using standard prenatal cfDNA screening. Here, we assess 22q11.2 microdeletion clinical performance by a prenatal cfDNA screen that incorporates fetal fraction (FF) amplification. METHODS: The study cohort consisted of patients who received Prequel (Myriad Genetics, Inc.), a prenatal cfDNA screening that incorporates FF amplification, and met additional eligibility criteria. Pregnancy outcomes were obtained via a routine process for continuous quality improvement. Samples with diagnostic testing results were used to calculate positive predictive value (PPV). RESULTS: 379,428 patients met study eligibility criteria, 76 of whom were screen-positive for a de novo 22q11.2 microdeletion. 22 (29.7%) had diagnostic testing results available, and all 22 cases were confirmed as true positives, for a PPV of 100% (95% CI 84.6%-100%). This performance was based on cases that ranged broadly across FF (5.9%-41.1%, mean 23.0%), body mass index (22.3-44.8, mean 29.9), and gestational age at testing (10.0w-34.6w, median 12.7w). Ultrasound findings in screen-positive pregnancies were consistent with those known to be associated with 22q11.2DS. CONCLUSION: 22q11.2 microdeletion screening that incorporates FF amplification demonstrated high PPV across both general and high-risk population cohorts.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Hammer C, Pierson S, Acevedo A, et al. High positive predictive value 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplification. Prenat Diagn. 2024. PMID: 38622914. doi:10.1002/pd.6562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。